Earnings History Data for Amicus Therapeutics, Inc. (FOLD) - NYSE NASDAQ

To lookup another company type a stock symbol and press 'Go'. The overview will show the earnings release info that is available in TheStockCatalyst database for the company.

For historic stock the Extended Hours price data shown are from just before market open on the day of release for premarket earnings releases and of the day after release for afterhours earnings releases. The normal price data is from just before market close on the days of release for premarket releases and the day after release for afterhours releases.

See the full list of available companies here.

Amicus Therapeutics, Inc.

AMICUS THERAPEUTICS is a biopharmaceutical company developing novel, oral therapeutics known as pharmacological chaperones for the treatment of a range of human genetic diseases. Pharmacological chaperone technology involves the use of small molecules that selectively bind to and stabilizeproteins in cells, leading to improved protein folding and trafficking, and increased activity. Amicus is initially targeting lysosomal storage disorders, which are severe, chronic genetic diseases with unmet medical needs. Amicus has completed Phase 2 clinical trials of Amigal(TM) for the treatment of Fabry disease and is conducting Phase 2 clinical trials of Plicera(TM) for the treatment of Gaucher disease.

Release Date	Time	Est. Time	Symbol	Name	Market Cap (M)	Rep. EPS	Est. EPS	Last years EPS	SeekingAlpha Headline	Price	Change	Ext. Hours Price	Ext. Hours Change	52 Week Range	Volume	Avg. Volume	Ext. Hours Volume
04-11-2025	PM		FOLD	Amicus Therapeutics, Inc.	2,780	N/A	0.05	0.04	Amicus Therapeutics GAAP EPS of -$0.38 misses by $0.42, revenue of $14.5B beats by $14.33B [11/4/2025 7:07 AM]	9.56	0.70 (7.84%)	8.95	0.09 (1.02%)	5.51 - 12.65	2,316,694	4,460,000	2,002
Google finance search Google investor relations search SeekingAlpha Zacks Finviz CNBC Yahoo Finance MarketWatch Nasdaq quote StockTwits TradingView AlphaQuery InvestorPlace ChartMill Amicus Therapeutics Q3 2025 Earnings Preview [11/3/2025 11:24 AM] Amicus Therapeutics GAAP EPS of -$0.38 misses by $0.42, revenue of $14.5B beats by $14.33B [11/4/2025 7:07 AM] Amicus Therapeutics Non-GAAP EPS of $0.18 beats by $0.06, revenue of $169.06M beats by $3.35M [11/4/2025 7:30 AM]
31-07-2025	PM		FOLD	Amicus Therapeutics, Inc.	1,890	-0.05	-0.05	0.01	Amicus Therapeutics Non-GAAP EPS of $0.01 misses by $0.01, revenue of $154.7M beats by $8.02M [7/31/2025 7:03 AM]	5.99	-0.14 (-2.28%)	6.35	0.22 (3.59%)	5.51 - 12.65	7,243,022	3,950,000	35,190
Amicus Therapeutics Q2 2025 Earnings Preview [7/30/2025 11:08 AM] Amicus Therapeutics Non-GAAP EPS of $0.01 misses by $0.01, revenue of $154.7M beats by $8.02M [7/31/2025 7:03 AM] Amicus reiterates $1B sales target for Galafold and Pombiliti/Opfolda by 2028 amid global expansion and Phase III pipeline progress [7/31/2025 3:13 PM]
01-05-2025	PM		FOLD	Amicus Therapeutics, Inc.	2,260	-0.05	0.01	-0.02	Amicus Therapeutics Non-GAAP EPS of $0.03 misses by $0.05, revenue of $125.2M misses by $11.15M [5/1/2025 7:08 AM]	6.70	-0.98 (-12.76%)	6.56	-1.12 (-14.58%)	6.20 - 12.65	9,627,116	3,970,000	14,236
Amicus Therapeutics Q1 2025 Earnings Preview [4/30/2025 3:05 PM] Amicus Therapeutics Non-GAAP EPS of $0.03 misses by $0.05, revenue of $125.2M misses by $11.15M [5/1/2025 7:08 AM] Amicus Therapeutics Announces First Quarter 2025 Financial Results and Corporate Updates [2025-05-01 07:00AM] Dimerix and Amicus Therapeutics Announce Exclusive License Agreement for DMX-200 in the United States [Apr-30-25 07:12PM]
19-02-2025	PM		FOLD	Amicus Therapeutics, Inc.	2,880	0.03	0.04	-0.11	Amicus Therapeutics beats FY topline estimates [2/19/2025 7:09 AM]	9.57	-0.28 (-2.84%)	9.86	0.01 (0.10%)	8.78 - 14.02	3,818,073	2,260,000	4,249
Amicus Therapeutics FY 2024 Earnings Preview [2/18/2025 2:43 PM] Amicus Therapeutics beats FY topline estimates [2/19/2025 7:09 AM] Amicus projects 17%-24% revenue growth in 2025, fueled by Fabry and Pompe therapies [2/19/2025 2:05 PM] Amicus Therapeutics Announces Full-Year 2024 Financial Results and Corporate Updates [2025-02-19 07:00AM]
06-11-2024	PM		FOLD	Amicus Therapeutics, Inc.	3,360	0.04	0.02	-0.07	Amicus Therapeutics Non-GAAP EPS of $0.10 beats by $0.05, revenue of $141.52M beats by $6.56M [11/6/2024 7:08 AM]	11.22	-0.52 (-4.39%)	12.50	0.76 (6.47%)	9.02 - 14.57	5,414,385	1,940,000	14,757
Amicus Therapeutics Q3 2024 Earnings Preview [11/5/2024 11:20 AM] Amicus Therapeutics Non-GAAP EPS of $0.10 beats by $0.05, revenue of $141.52M beats by $6.56M [11/6/2024 7:08 AM] Amicus Therapeutics Announces Third Quarter 2024 Financial Results and Corporate Updates [2024-11-06 07:00AM]
08-08-2024	PM		FOLD	Amicus Therapeutics, Inc.	2,940	0.01	-0.04	-0.15	Amicus Therapeutics Non-GAAP EPS of $0.06 beats by $0.04, revenue of $126.67M beats by $5.43M [8/8/2024 7:12 AM]	11.26	1.26 (12.55%)	10.90	0.90 (9.00%)	9.02 - 14.57	3,969,620	3,440,000	449
Amicus Therapeutics Q2 2024 Earnings Preview [8/7/2024 11:16 AM] Amicus Therapeutics Non-GAAP EPS of $0.06 beats by $0.04, revenue of $126.67M beats by $5.43M [8/8/2024 7:12 AM]
09-05-2024	PM		FOLD	Amicus Therapeutics, Inc.	3,080	-0.02	-0.06	-0.18	Amicus Therapeutics reports mixed Q1 results; updates FY24 outlook [5/9/2024 7:16 AM]	9.48	-0.66 (-6.46%)	10.00	-0.14 (-1.38%)	9.24 - 14.57	4,624,708	2,420,000	827
Amicus Therapeutics reports mixed Q1 results; updates FY24 outlook [5/9/2024 7:16 AM] Amicus Therapeutics Q1 2024 Earnings Preview [5/8/2024 2:18 PM]
28-02-2024	PM		FOLD	Amicus Therapeutics	3,968	-0.11	-0.06	0.00	Amicus Therapeutics Non-GAAP EPS of $0.01 beats by $0.05, revenue of $115.08M in-line [2/28/2024 7:09 AM]	12.96	-0.89 (-6.43%)	13.78	-0.07 (-0.51%)	9.70 - 14.57	4,021,545	3,700,000	11,315
Amicus Therapeutics Q4 2023 Earnings Preview [2/27/2024 12:23 PM] Amicus Therapeutics Non-GAAP EPS of $0.01 beats by $0.05, revenue of $115.08M in-line [2/28/2024 7:09 AM]
08-11-2023	PM		FOLD	Amicus Therapeutics, Inc.	3,250	-0.07	-0.08	-0.12	Amicus Therapeutics beats Q3 top and bottom line estimates; raises FY23 Galafold revenue outlook [11/8/2023 7:06 AM]	11.36	-0.35 (-2.99%)	11.36	0.0 (0.00%)	10.04 - 14.10	2,526,709	2,600,000	14,782
Amicus Therapeutics Q3 2023 Earnings Preview [11/7/2023 11:53 AM] Amicus Therapeutics beats Q3 top and bottom line estimates; raises FY23 Galafold revenue outlook [11/8/2023 7:06 AM]
08-08-2023	PM		FOLD	Amicus Therapeutics, Inc.	3,740	-0.15	-0.12	-0.21	Amicus Therapeutics reports mixed Q2 earnings; updates FY23 outlook [8/8/2023 7:10 AM]	13.82	1.29 (10.25%)	13.35	0.81 (6.46%)	9.10 - 13.85	4,177,836	3,440,000	250
Amicus Therapeutics Q2 2023 Earnings Preview [8/7/2023 1:36 PM] Amicus Therapeutics reports mixed Q2 earnings; updates FY23 outlook [8/8/2023 7:10 AM]
10-05-2023	PM	7:00 AM ET (May 10)	FOLD	Amicus Therapeutics, Inc.	3,440	-0.18	-0.13	-0.30	Amicus Therapeutics GAAP EPS of -$0.18 misses by $0.03, revenue of $86.27M beats by $3.06M [5/10/2023 7:04 AM]	11.59	-0.60 (-4.92%)	12.05	-0.14 (-1.15%)	6.23 - 13.84	2,073,089	2,830,000	2,130
Amicus Therapeutics Q1 2023 Earnings Preview [5/9/2023 12:12 PM] Amicus Therapeutics GAAP EPS of -$0.18 misses by $0.03, revenue of $86.27M beats by $3.06M [5/10/2023 7:04 AM]
01-03-2023	PM	7:00 AM ET (Mar 1)	FOLD	Amicus Therapeutics, Inc.	3,670	-0.19	-0.13	-0.29	Amicus Therapeutics reports mixed Q4 earnings; initiates FY23 outlook [3/1/2023 7:05 AM]	13.58	0.39 (2.96%)	0.0	0.0 (0.00%)	5.91 - 13.84	2,225,339	2,560,000	0
Amicus Therapeutics FY 2022 Earnings Preview [2/28/2023 1:03 PM] Amicus Therapeutics reports mixed Q4 earnings; initiates FY23 outlook [3/1/2023 7:05 AM]
07-11-2022	PM	7:00 AM ET (Nov 7)	FOLD	Amicus Therapeutics, Inc.	2,830	-0.12	-0.19	-0.19	Amicus Therapeutics reports mixed Q3 earnings; updates FY22 guidance [11/7/2022 7:03 AM]	10.30	0.19 (1.88%)	9.94	-0.17 (-1.68%)	5.91 - 12.96	2,943,461	2,930,000	4,032
Amicus Therapeutics reports mixed Q3 earnings; updates FY22 guidance [11/7/2022 7:03 AM] Amicus says no oral explanations in EU for lead program [11/7/2022 1:10 PM]
04-08-2022	PM	7:00 AM ET (Aug 4)	FOLD	Amicus Therapeutics, Inc.	2,870	-0.21	-0.23	-0.19		10.89	0.53 (5.06%)	10.37	0.0 (0.00%)	5.91 - 12.63	1,794,867	2,470,000	1,001
Amicus Therapeutics Q2 2022 Earnings Preview [8/3/2022 12:06 PM] Amicus Therapeutics reports mixed Q2 earnings; reaffirms FY22 guidance [8/4/2022 7:10 AM]
09-05-2022	PM	7:00 AM ET (May 9)	FOLD	Amicus Therapeutics, Inc.	1,850	-0.30	-0.24	-0.25	Amicus Therapeutics GAAP EPS of -$0.30 misses by $0.04, revenue of $78.7M beats by $1.56M; updates FY22 guidance [5/9/2022 7:03 AM]	6.20	-0.07 (-1.20%)	6.46	0.19 (3.03%)	5.91 - 12.63	8,432,714	4,470,000	502
Amicus Therapeutics GAAP EPS of -$0.30 misses by $0.04, revenue of $78.7M beats by $1.56M; updates FY22 guidance [5/9/2022 7:03 AM] Aerie (AERI) Q1 Loss Wider Than Expected, Revenues Rise Y/Y [May-06-22 03:48PM] ChemoCentryx (CCXI) Q1 Earnings and Sales Miss Estimates [May-06-22 03:38PM] Intellia (NTLA) Q1 Loss Wider Than Expected, Revenues Beat [May-06-22 03:02PM] Insiders who bought stock earlier this year lose -US$61k as Amicus Therapeutics, Inc. (NASDAQ:FOLD) drops to US$1.9b [May-06-22 09:44AM] Why Amicus (FOLD) Might Surprise This Earnings Season [May-06-22 08:40AM] Amicus Therapeutics Announces First Quarter 2022 Financial Results [May-09-22 07:00AM] CORRECTING AND REPLACING -- Amicus Therapeutics Announces First Quarter 2022 Financial Results [May-09-22 09:15AM] Amicus Therapeutics (FOLD) Reports Q1 Loss, Tops Revenue Estimates [May-09-22 08:25AM]
24-02-2022	PM	7:00 AM ET (Feb 24)	FOLD	Amicus Therapeutics, Inc.	2,420	-0.29	-0.14	-0.27	Amicus Therapeutics GAAP EPS of -$0.92 misses by $0.16, revenue of $305.51M misses by $1.21M [2/24/2022 7:03 AM]	8.92	-0.34 (-3.67%)	0.0	0.0 (0.00%)	8.40 - 20.15	738,794	2,586,816	0
Amicus Therapeutics FY 2021 Earnings Preview [2/23/2022 11:38 AM] Amicus Therapeutics GAAP EPS of -$0.92 misses by $0.16, revenue of $305.51M misses by $1.21M [2/24/2022 7:03 AM] Amicus, SPAC ARYA mutually terminate business combination for Caritas Therapeutics [2/24/2022 7:40 AM] Amicus Therapeutics Announces Full-Year 2021 Financial Results and Corporate Updates [Feb-24-22 07:00AM] ARYA Sciences Acquisition Corp IV and Amicus Therapeutics, Inc. Mutually Agree to Terminate Business Combination Agreement With Respect to the Acquisition of Amicus Gene Therapy Business Due to Market Conditions [Feb-24-22 07:00AM] Amicus Therapeutics (FOLD) Reports Q4 Loss, Lags Revenue Estimates [Feb-24-22 10:35AM]
09-11-2021	PM	7:00 AM ET (Nov 9)	FOLD	Amicus Therapeutics, Inc.	3,330	-0.19	-0.18	-0.22	Amicus Therapeutics EPS misses by $0.02, misses on revenue [11/9/2021 7:02 AM]	11.34	-0.59 (-4.95%)	11.73	-0.20 (-1.68%)	8.60 - 25.39	1,427,395	2,320,000	106,400
Amicus Therapeutics Q3 2021 Earnings Preview [11/8/2021 3:01 PM] Amicus Therapeutics EPS misses by $0.02, misses on revenue [11/9/2021 7:02 AM] Amicus Therapeutics Announces Third Quarter 2021 Financial Results and Corporate Updates [Nov-09-21 07:00AM] Amicus Therapeutics (FOLD) Reports Q3 Loss, Lags Revenue Estimates [Nov-09-21 08:25AM] Amicus Therapeutics, inc (FOLD) Q3 2021 Earnings Call Transcript [Nov-09-21 04:00PM]
05-08-2021	PM	7:00 AM ET (Aug 5)	FOLD	Amicus Therapeutics, Inc.	2,470	-0.19	-0.21	-0.20	Amicus Therapeutics EPS beats by $0.02, beats on revenue [8/5/2021 7:07 AM]	10.06	0.39 (3.98%)	9.85	0.17 (1.76%)	8.60 - 25.39	1,840,505	2,300,000	41,135
Amicus Therapeutics EPS beats by $0.02, beats on revenue [8/5/2021 7:07 AM] Amicus Therapeutics to Present at the BTIG Virtual Biotechnology Conference [Aug-04-21 07:00AM] Amicus Therapeutics Announces Second Quarter 2021 Financial Results and Corporate Updates [Aug-05-21 07:00AM] Amicus Therapeutics (FOLD) Reports Q2 Loss, Tops Revenue Estimates [Aug-05-21 08:35AM] Amicus Therapeutics, inc (FOLD) Q2 2021 Earnings Call Transcript [Aug-05-21 07:00PM]
10-05-2021	PM	7:00 AM ET (May 10)	FOLD	Amicus Therapeutics, Inc.	2,740	-0.25	-0.23	-0.35	Amicus Therapeutics EPS misses by $0.01, misses on revenue [5/10/2021 7:04 AM]	9.39	-0.36 (-3.69%)	9.81	0.06 (0.62%)	8.83 - 25.39	1,759,098	2,330,000	91,660
Amicus Therapeutics EPS misses by $0.01, misses on revenue [5/10/2021 7:04 AM] Amicus Therapeutics posts pandemic hit Q1 earnings miss [5/10/2021 7:52 AM] Amicus Therapeutics to Present at Upcoming Investor Conferences in May 2021 [May-07-21 07:00AM] Amicus Therapeutics, Inc. to Host Earnings Call [May-10-21 06:45AM] Amicus Therapeutics Announces First Quarter 2021 Financial Results and Corporate Updates [May-10-21 07:00AM] Amicus Therapeutics (FOLD) Reports Q1 Loss, Lags Revenue Estimates [May-10-21 09:05AM] Amicus Therapeutics Inc (FOLD) Q1 2021 Earnings Call Transcript [May-10-21 06:30PM]
01-03-2021	PM	7:00 AM ET (Mar 1)	FOLD	Amicus Therapeutics, Inc.	3,180	-0.27	-0.21	-0.35	Amicus Therapeutics EPS misses by $0.08, beats on revenue [3/1/2021 7:06 AM]	11.76	-0.52 (-4.19%)	12.40	0.12 (0.98%)	6.25 - 25.39	5,041,692	8,852,331	32,376
Amicus Therapeutics EPS misses by $0.08, beats on revenue; FY21 outlook [3/1/2021 7:06 AM] Amicus Therapeutics FY 2020 top line up 43% [3/1/2021 10:08 AM] Amicus Therapeutics Announces Full-Year 2020 Financial Results and Corporate Updates [Mar-01-21 07:00AM] Amicus Therapeutics, Inc. to Host Earnings Call [Mar-01-21 06:30AM] Earnings Preview for Amicus Therapeutics [Feb-26-21 10:10AM]
05-11-2020	PM	7:00 AM ET (Nov 5)	FOLD	Amicus Therapeutics, Inc.	4,910	-0.22	-0.20	-0.24	Amicus Therapeutics EPS misses by $0.04, beats on revenue [11/5/2020 7:08 AM]	21.34	0.60 (2.89%)	21.34	0.0 (0.00%)	6.25 - 21.72	2,607,476	2,228,011	21,582

10-08-2020	PM	7:00 AM ET (Aug 10)	FOLD	Amicus Therapeutics, Inc.	3,960	-0.20	-0.26	-0.34	Amicus Therapeutics EPS beats by $0.07, beats on revenue [8/10/2020 7:07 AM]	15.22	-0.19 (-1.23%)	15.35	-0.06 (-0.39%)	6.25 - 16.13	632,446	2,065,793	15,770